open access

Vol 91, No 2 (2020)
ORIGINAL PAPERS Gynecology
Published online: 2020-02-28
Get Citation

Increased osteopontin expression in endometrial carcinoma is associated with better survival outcome

Haneen Al Maghrabi, Wafaey Gomaa, Jaudah Al-Maghrabi
DOI: 10.5603/GP.2020.0020
·
Pubmed: 32141052
·
Ginekol Pol 2020;91(2):73-78.

open access

Vol 91, No 2 (2020)
ORIGINAL PAPERS Gynecology
Published online: 2020-02-28

Abstract

Objectives: Osteopontin (OPN) is a key extracellular matrix protein that is involved in cancer progression. The aim of the
current study is to investigate the relation of OPN immunostaining in endometrial carcinoma with clinicopathological
parameters.
Material and methods: Archival 71 endometrial carcinomas and 30 non-neoplastic endometrial tissues were obtained from
the Department of Pathology at King Abdulaziz University Jeddah, Saudi Arabia. Tissue microarrays were constructed. Tissue
sections were stained using anti-human OPN monoclonal antibody. Immunostaining results were recorded and analysed.
Results: In non-neoplastic endometrial tissues, high (increased) OPN immunostaining was observed in 100%. In endometrial
carcinoma, high (increased) OPN immunostaining was seen in 64.8% of cases. High (increased) OPN immunostaining
was more frequent in non-neoplastic tissues than in endometrial carcinoma (p < 0.001). OPN immunostaining showed no
association with histological type, FIGO tumour grade, tumour size, myometrial invasion, lymphovascular invasion, surgical
resection margin or lymph node metastasis. On the other hand, high (increased) OPN immunostaining was associated with
better overall survival [Log Rank (Mantel-Cox) = 4.385, p = 0.003].
Conclusions: In endometrial carcinoma, immunohistochemical staining of OPN could be a helpful tool in the prediction
survival pattern. OPN immunostaining showed no association with most clinicopathological features. Further investigations
both clinical and molecular are needed to explore the downstream of OPN in endometrial carcinoma.

Abstract

Objectives: Osteopontin (OPN) is a key extracellular matrix protein that is involved in cancer progression. The aim of the
current study is to investigate the relation of OPN immunostaining in endometrial carcinoma with clinicopathological
parameters.
Material and methods: Archival 71 endometrial carcinomas and 30 non-neoplastic endometrial tissues were obtained from
the Department of Pathology at King Abdulaziz University Jeddah, Saudi Arabia. Tissue microarrays were constructed. Tissue
sections were stained using anti-human OPN monoclonal antibody. Immunostaining results were recorded and analysed.
Results: In non-neoplastic endometrial tissues, high (increased) OPN immunostaining was observed in 100%. In endometrial
carcinoma, high (increased) OPN immunostaining was seen in 64.8% of cases. High (increased) OPN immunostaining
was more frequent in non-neoplastic tissues than in endometrial carcinoma (p < 0.001). OPN immunostaining showed no
association with histological type, FIGO tumour grade, tumour size, myometrial invasion, lymphovascular invasion, surgical
resection margin or lymph node metastasis. On the other hand, high (increased) OPN immunostaining was associated with
better overall survival [Log Rank (Mantel-Cox) = 4.385, p = 0.003].
Conclusions: In endometrial carcinoma, immunohistochemical staining of OPN could be a helpful tool in the prediction
survival pattern. OPN immunostaining showed no association with most clinicopathological features. Further investigations
both clinical and molecular are needed to explore the downstream of OPN in endometrial carcinoma.

Get Citation

Keywords

endometrial carcinoma; tissue microarray; immunohistochemistry; osteopontin

About this article
Title

Increased osteopontin expression in endometrial carcinoma is associated with better survival outcome

Journal

Ginekologia Polska

Issue

Vol 91, No 2 (2020)

Pages

73-78

Published online

2020-02-28

DOI

10.5603/GP.2020.0020

Pubmed

32141052

Bibliographic record

Ginekol Pol 2020;91(2):73-78.

Keywords

endometrial carcinoma
tissue microarray
immunohistochemistry
osteopontin

Authors

Haneen Al Maghrabi
Wafaey Gomaa
Jaudah Al-Maghrabi

References (29)
  1. Du Xl, Jiang T, Sheng Xg, et al. Inhibition of osteopontin suppresses in vitro and in vivo angiogenesis in endometrial cancer. Gynecol Oncol. 2009; 115(3): 371–376.
  2. Smyth NA, Murawski CD, Adams SB, et al. International Consensus Group on Cartilage Repair of the Ankle. Osteochondral Allograft: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle. Foot Ankle Int. 2018; 39(1_suppl): 35S–40S.
  3. Brown LF, Berse B, Van de Water L, et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell. 1992; 3(10): 1169–1180.
  4. Ritter NM, Farach-Carson MC, Butler WT. Evidence for the formation of a complex between osteopontin and osteocalcin. J Bone Miner Res. 1992; 7(8): 877–885.
  5. Rodrigues LR, Teixeira JA, Schmitt FL, et al. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(6): 1087–1097.
  6. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001; 276(48): 44926–44935.
  7. Li Y, Xie Y, Cui D, et al. Osteopontin Promotes Invasion, Migration and Epithelial-Mesenchymal Transition of Human Endometrial Carcinoma Cell HEC-1A Through AKT and ERK1/2 Signaling. Cell Physiol Biochem. 2015; 37(4): 1503–1512.
  8. Hahne JC, Meyer SR, Kranke P, et al. Studies on the role of osteopontin-1 in endometrial cancer cell lines. Strahlenther Onkol. 2013; 189(12): 1040–1048.
  9. Senger D, Wirth D, Hynes R. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979; 16(4): 885–893.
  10. Assidi M, Gomaa W, Jafri M, et al. Prognostic value of Osteopontin (SPP1) in colorectal carcinoma requires a personalized molecular approach. Tumour Biol. 2019; 41(9): 1010428319863627.
  11. Furger KA, Menon RK, Tuck AB, et al. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med. 2001; 1(5): 621–632.
  12. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998; 79(2): 127–132.
  13. Chambers AF, Wilson SM, Kerkvliet N, et al. Osteopontin expression in lung cancer. Lung Cancer. 1996; 15(3): 311–323.
  14. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998; 79(5): 502–508.
  15. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004; 90(10): 1877–1881.
  16. Gomaa W, Al-Ahwal M, Hamour O, et al. Osteopontin cytoplasmic immunoexpression is a predictor of poor disease-free survival in thyroid cancer. Journal of Microscopy and Ultrastructure. 2013; 1(1): 8.
  17. Al-Maghrabi J, Emam E, Gomaa W, et al. c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence. BMC Cancer. 2015; 15: 676.
  18. Gomaa W, Ke Y, Fujii H, et al. Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67. Virchows Arch. 2005; 447(4): 701–709.
  19. Gomaa W, Al-Ahwal M, Hamour O, et al. Osteopontin cytoplasmic immunoexpression is a predictor of poor disease-free survival in thyroid cancer. Journal of Microscopy and Ultrastructure. 2013; 1(1): 8.
  20. Wei R, Wong JP, Kwok HF. Osteopontin -- a promising biomarker for cancer therapy. J Cancer. 2017; 8(12): 2173–2183.
  21. Castello LM, Raineri D, Salmi L, et al. Osteopontin at the Crossroads of Inflammation and Tumor Progression. Mediators Inflamm. 2017; 2017: 4049098.
  22. Briese J, Schulte HM, Bamberger CM, et al. Expression pattern of osteopontin in endometrial carcinoma: correlation with expression of the adhesion molecule CEACAM1. Int J Gynecol Pathol. 2006; 25(2): 161–169.
  23. von Wolff M, Strowitzki T, Becker V, et al. Endometrial osteopontin, a ligand of beta3-integrin, is maximally expressed around the time of the "implantation window". Fertil Steril. 2001; 76(4): 775–781.
  24. Casals G, Ordi J, Creus M, et al. Osteopontin and alphavbeta3 integrin as markers of endometrial receptivity: the effect of different hormone therapies. Reprod Biomed Online. 2010; 21(3): 349–359.
  25. Casals G, Ordi J, Creus M, et al. Osteopontin and alphavbeta3 integrin expression in the endometrium of infertile and fertile women. Reprod Biomed Online. 2008; 16(6): 808–816.
  26. Cho H, Kang ES, Kim YT, et al. Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest. 2009; 27(3): 313–323.
  27. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004; 444(3): 213–223.
  28. Hashiguchi Y, Tsuda H, Bandera CA, et al. Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer. Med Oncol. 2006; 23(2): 205–212.
  29. Ramachandran S, Kwon KY, Shin SJ, et al. Regulatory role of osteopontin in malignant transformation of endometrial cancer. Mol Biol Rep. 2013; 40(5): 3623–3629.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl